vimarsana.com
Home
Live Updates
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators : vimarsana.com
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
JENA, Germany, May 21, 2024 -- InflaRx N.V. , a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American...
Related Keywords
San Diego
,
California
,
United States
,
Germany
,
Munich
,
Bayern
,
American
,
Inflarx Gmb
,
Regina Lutz
,
Camilla Chong
,
Laurie Doyle
,
Jan Medina
,
Katja Arnold
,
Globenewswire Inc
,
Inflarx Pharmaceuticals Inc
,
Inflarx Commitment Program
,
Drug Administration
,
American Thoracic Society
,
International Conference
,
European Medicines Agency
,
Mc Services
,
Thoracic Society
,
Baricitinib Dramatically Improves Mortality
,
Critically Ill
,
Acute Respiratory Failure
,
Chief Medical Officer
,
Fact Sheet
,
Healthcare Providers
,
Safety Information
,
Marketing Authorization Application
,
Medicines Agency
,
vimarsana.com © 2020. All Rights Reserved.